Skip to main content
. 2013 Jul 12;1(5):911–917. doi: 10.3892/mco.2013.146

Figure 2.

Figure 2

Kaplan-Meier estimates for the overall survival (OS) outcome of peripheral T-cell non-Hodgkin lymphoma (PTCL) patients with different treatments. The estimated OS rate in the intensive chemotherapy group (33.9%) was significantly higher compared to that in the CHOP therapy group (11.9%). Cum, cumulative; CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone.